Macrophage-Targeting Agonist Antibody
Undisclosed Solid Tumors
Phase 1Available for Partnering
Key Facts
Indication
Undisclosed Solid Tumors
Phase
Phase 1
Status
Available for Partnering
Company
About Bolt Biotherapeutics
Bolt Biotherapeutics is developing targeted immunotherapies based on its proprietary Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform, which aims to harness the innate immune system to fight cancer. Founded in 2015 on foundational research from Stanford University, the company's strategy centers on advancing its lead clinical asset, BDC-4182, and leveraging collaborations to expand its pipeline. As a pre-revenue public company, Bolt faces the critical challenge of generating compelling clinical proof-of-concept data to validate its platform and attract further investment or partnership capital in a competitive oncology landscape.
View full company profileTherapeutic Areas
Other Undisclosed Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| IMA204 | Immatics Biotechnologies | Phase 1 |
| TAR002 | TargImmune Therapeutics | Pre-clinical |
| TAR003 | TargImmune Therapeutics | Pre-clinical |
| Proprietary TCR-NK Platform | Zelluna Immunotherapy | Preclinical |
| ERAS-113 | Erasca | Discovery |
| Multiple Programs | Aktis Oncology | Discovery |
| BAT5506 | Compugen | Preclinical |
| Precision DACs | Prelude Therapeutics | Discovery |
| V2ACT Immunotherapy | Genelux | Phase 1 |
| ATOR-4066 | alligator-bioscience-ab | Discovery/Preclinical |
| ACR-6840 | Acrivon Therapeutics | Preclinical |
| ADC Program | Lantern Pharma | Discovery/Preclinical |